106 related articles for article (PubMed ID: 24261759)
1. Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases.
Ito S; Ogishima H; Kondo Y; Sugihara M; Hayashi T; Chino Y; Goto D; Matsumoto I; Sumida T
Mod Rheumatol; 2014 Jan; 24(1):52-9. PubMed ID: 24261759
[TBL] [Abstract][Full Text] [Related]
2. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
[TBL] [Abstract][Full Text] [Related]
3. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
Kim MK; Suk JH; Kwon MJ; Chung HS; Yoon CS; Jun HJ; Ko JH; Kim TK; Lee SH; Oh MK; Rhee BD; Park JH
Diabetes Res Clin Pract; 2011 Jun; 92(3):322-8. PubMed ID: 21376417
[TBL] [Abstract][Full Text] [Related]
4. Nateglinide (Starlix): update on a new antidiabetic agent.
Phillips LS; Dunning BE
Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
[TBL] [Abstract][Full Text] [Related]
5. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
7. Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients.
Zheng F; Yin X; Lu W; Zhou J; Yuan H; Li H
J Endocrinol Invest; 2013; 36(7):489-96. PubMed ID: 23324437
[TBL] [Abstract][Full Text] [Related]
8. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
[TBL] [Abstract][Full Text] [Related]
9. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
[TBL] [Abstract][Full Text] [Related]
10. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.
Kato T; Inoue T; Node K
Cardiovasc Diabetol; 2010 Mar; 9():12. PubMed ID: 20334663
[TBL] [Abstract][Full Text] [Related]
11. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
12. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
13. [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
Hirose T
Nihon Rinsho; 2005 Dec; 63(12):2237-44. PubMed ID: 16363700
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study.
Islas-Andrade S; Revilla-Monsalve MC; Martínez de Hurtado E; Chacín LF; Caminos QR; Yupanqui H; López G; de la Torre W;
Pharmacology; 2003 Jun; 68(2):89-95. PubMed ID: 12711836
[TBL] [Abstract][Full Text] [Related]
16. [Clinical observation on improving senile postprandial hyperglycemia and insulin sensitivity with combination of acarbose and liuwei nengxiao capsule].
Yu W; Gao YY; Zhang X
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 May; 24(5):396-9. PubMed ID: 15199620
[TBL] [Abstract][Full Text] [Related]
17. [A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus].
Pan CY; Gao Y; Li GW; Zhu XX; Gao X; Liu X
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):304-7. PubMed ID: 19576120
[TBL] [Abstract][Full Text] [Related]
18. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction.
den Uyl D; van Raalte DH; Nurmohamed MT; Lems WF; Bijlsma JW; Hoes JN; Dijkmans BA; Diamant M
Arthritis Rheum; 2012 Mar; 64(3):639-46. PubMed ID: 21953589
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases.
Uzu T; Harada T; Sakaguchi M; Kanasaki M; Isshiki K; Araki S; Sugiomoto T; Koya D; Haneda M; Kashiwagi A; Yamauchi A
Nephron Clin Pract; 2007; 105(2):c54-7. PubMed ID: 17135768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
